Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003222 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00003222 is a Phase 2 study that has completed, run by University of Virginia. The registered enrollment target is 40 participants.
The verdict
NCT00003222, a Phase 2 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to and kill tumor cells. Colony-stimulating factors such as GM-CSF may increase the number of immune cells found in the bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy with GM-CSF and interleukin-2 may be kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccines made from melanoma cells with or without GM-CSF followed by interleukin-2 in treating patients with stage III or stage IV melanoma.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL sargramostim
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL gp100 antigen
- BIOLOGICAL tetanus peptide melanoma vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1998-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003222
The ClinicalTrials.gov registry entry for NCT00003222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which aldesleukin is the first listed.
NCT00003222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003222 about?
NCT00003222 is a clinical study titled "Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to and kill tumor cells. Colony-stimulating factors such as GM-CSF may increase the number of immune cells found in the bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to...
What is the current status of trial NCT00003222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1998-04.
What interventions are being tested in trial NCT00003222?
The interventions under investigation include: aldesleukin (BIOLOGICAL), sargramostim (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), gp100 antigen (BIOLOGICAL), tetanus peptide melanoma vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003222?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.